Valsts: Zviedrija
Valoda: zviedru
Klimata pārmaiņas: Läkemedelsverket (Medical Products Agency)
terazosinhydrokloriddihydrat
STADA Arzneimittel AG
G04CA03
terazosin hydrochloride dihydrate
2 mg
Tablett
para-orange Hjälpämne; terazosinhydrokloriddihydrat 2,374 mg Aktiv substans; laktosmonohydrat Hjälpämne
Receptbelagt
Terazosin
Avregistrerad
2002-11-29
1 PACKAGE LEAFLET: INFORMATION FOR THE USER TERAZOSTAD 1 MG, 2 MG, 5 MG, 10 MG AND 1 MG + 2 MG TABLETS Terazosin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Terazostad is and what it is used for 2. Before you take Terazostad 3. How to take Terazostad 4. Possible side effects 5. How to store Terazostad 6. Further information 1. WHAT TERAZOSTAD IS AND WHAT IT IS USED FOR Terazostad belongs to a group of medicines called alpha blockers. It works by relaxing the blood vessels making it easier for the blood to flow through. It can also relax the muscle of the bladder and bladder exit. TERAZOSTAD IS USED TO: treat mild to moderate high blood pressure (hypertension). treat urinary problems due to a condition called benign prostatic hyperplasia (BPH). This condition is caused by overgrowth of the prostate gland and is common in older men. When the prostate gland grows too big, it can partially block the flow of urine out of the bladder. This leads to symptoms such as: a weak or intermittent flow of urine a need to pass water more frequently or at night a sudden need to pass water. 2. BEFORE YOU TAKE TERAZOSTAD DO NOT TAKE TERAZOSTAD If you are allergic (hypersensitive) to terazosin, or to a structurally similar alpha-adrenergic antagonist, the colourant “sunset yellow” FCF (E 110) or to any of the other ingredients of the Terazostad tablets (see section 6 “Further information” at the end of the leaflet) 2 If you suffer or have ever suffered from micturition syncope. This is a brief loss of consciousness that occurs when passing w Izlasiet visu dokumentu
1 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Terazostad 1 mg tablets Terazostad 2 mg tablets Terazostad 5 mg tablets Terazostad 10 mg tablets Terazostad 1 mg + 2 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains terazosin 1 mg, 2 mg, 5 mg or 10 mg (as terazosin hydrochloride dihydrate). For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet 1 mg tablet: white, round tablet 2 mg tablet: orange, round tablet, with a break mark on one side. The tablet can be divided into equal halves. 5 mg tablet: red, round tablet 10 mg tablet: blue, round tablet 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Terazostad tablets are indicated for: the treatment of mild to moderate hypertension symptomatic treatment of urinary obstruction caused by benign prostatic hyperplasia (BPH). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults: For the treatment of hypertension: The dose of terazosin should be managed according to each patients response. The starting dose for all patients is 1 mg before bedtime and this should not be exceeded during the first week of treatment. Patients should be advised to comply in order to avoid first-dose hypotensive effect. The dose can be increased by approximately doubling the dose at weekly intervals until effective control of blood pressure is established. The usual maintenance dose is 2 mg daily. However, for certain patients, an increased dose may become necessary. A maximum dose of 20 mg should not be exceeded. Reduction of dose should be undertaken when adding other antihypertensive medication followed by re-titration if required. 2 For the treatment of Benign Prostatic Hyperplasia (BPH): The dose of terazosin should be managed according to each patients response. The starting dose for all patients is 1 mg at night-time for 7 days and this should not be exceeded during the first week of treatment. The dose can then be increased to 2 mg daily for 14 days, followed -if necessary- by 5 mg daily for 7 days. Response t Izlasiet visu dokumentu